Rep. Gus M. Bilirakis

Maddy summaryThis bill reauthorizes funding for the C.W. Bill Young Cell Transplantation Program, setting $31 million for fiscal year 2025 and $33 million annually for fiscal years 2027-2031. It also extends the deadline for the national cord blood inventory program from 2026 to 2031. The legislation directly affects stem cell research programs and cord blood banks by maintaining federal funding levels and prolonging the inventory program’s timeline. These provisions ensure continuity for existing research infrastructure and blood bank operations without introducing new policy changes.

Maddy summaryThe AADAPT Act reauthorizes and expands Project ECHO grants to improve Alzheimer’s and dementia care through technology-enabled training. It specifically funds grants for healthcare providers in rural, frontier, or medically underserved areas to enhance early diagnosis, quality care, and provider retention for dementia patients. The bill authorizes $1 million annually (2027-2032) for these dementia-focused training programs, requiring funds to supplement - not replace - existing resources. This directly supports primary care providers licensed to serve underserved communities, using collaborative online learning to address care gaps.

Maddy summaryHR 2821, the FDA Modernization Act 3.0, requires the FDA to update regulatory language within one year of enactment. It directs the agency to replace all references to "animal tests" with "nonclinical tests" in 22 specific sections of the Code of Federal Regulations related to drug development and approval processes. The bill also adds a definition for "nonclinical test" into relevant FDA regulations to align with prior legislative changes. This update applies directly to pharmaceutical manufacturers and FDA reviewers who follow these regulatory guidelines during drug development. The changes aim to modernize terminology without altering current testing requirements.

Maddy summaryHR 2715, the *Destruction of Hazardous Imports Act*, expands the authority to destroy imported goods that pose public health risks. It amends the Federal Food, Drug, and Cosmetic Act to allow the Secretary of Health and Human Services to order the destruction of any refused import (not just drugs or devices) if it presents a significant health concern. The bill also prohibits the unauthorized movement, sale, or export of such refused goods. These changes apply to importers of hazardous refused articles 180 days after enactment, with the FDA required to finalize implementing regulations within 90 days.

Maddy summaryHR 2004, titled "Tyler’s Law," requires the Secretary of Health and Human Services to study how often hospital emergency departments test for fentanyl during overdose cases (beyond standard drug tests), including associated costs, patient benefits/risks, and impacts on privacy and patient-physician relationships. The study must be completed within one year of the bill's enactment. Based on the study results, the Secretary must issue guidance within six months on whether emergency departments should routinely test for fentanyl, how to inform clinicians about test contents, and how such testing may affect future overdose risks and health outcomes. This bill directly affects hospital emergency departments and patients experiencing overdoses by shaping future testing protocols.

Maddy summaryHR 1266, the Combating Illicit Xylazine Act, adds xylazine - a veterinary sedative increasingly found in illicit drug mixtures - to Schedule III of the Controlled Substances Act, regulating its use and trafficking. It directly affects veterinarians, animal owners, and manufacturers by allowing xylazine to be legally dispensed for animal use under specific veterinary prescriptions, while prohibiting non-veterinary human use. The bill includes transition periods (60 days for practitioners, 1 year for labeling) to ease compliance for manufacturers and practitioners, and requires the DEA and FDA to expedite necessary applications. It also mandates two congressional reports on xylazine's illicit use and trafficking patterns, and directs the Sentencing Commission to review penalties for offenses involving xylazine.

Maddy summaryThe Take Care of America's Veterans Act is a comprehensive legislative bill designed to improve benefits, healthcare access, and administrative efficiency for veterans and their families. The bill directly affects veterans, their surviving spouses, caregivers, and the Department of Veterans Affairs (VA). Key provisions include expanding disability compensation for combat-related retirees, allowing remarried surviving spouses to retain certain survivor benefits, and increasing compensation rates for specific disability conditions like sleep apnea and tinnitus. The legislation also mandates significant healthcare improvements, such as establishing a pilot program to coordinate care between the VA and Medicare, creating a formulary for prosthetic items, and requiring the VA to provide lactation spaces in all medical centers. Additionally, the bill introduces administrative reforms to speed up claims processing, prohibit denying claims solely for missed medical appointments, and enhance oversight of the VA's disability rating system.

Maddy summaryThe Patients First Act of 2026 modifies how Medicare reimburses physicians and primary care providers to improve access and stabilize payments. It establishes a new hybrid payment model for primary care services from 2027 to 2031, which pays a monthly fee per patient to eligible independent practices while covering specific services like care management and telehealth without cost-sharing for patients. The bill also updates the formula for calculating reimbursement rates to account for high inflation years and requires more frequent updates to the costs used in calculating payments. Additionally, the legislation reforms the performance-based payment system by adding care efficiency measures, creating a task force to recommend new quality metrics, and adjusting penalties for providers who fail to report on certain data.

Maddy summaryHR 7651, the Chloe Cole Act of 2026, prohibits healthcare providers from performing certain medical interventions on minors under 18 aimed at altering physical development to align with gender identity. These "covered interventions" include puberty blockers, hormone treatments, and specific surgeries, but exclude medically necessary care for conditions like disorders of sexual development or traumatic injuries. The bill creates a federal civil lawsuit right for affected minors or their parents against providers who perform such interventions, allowing claims for damages including emotional distress and punitive awards, with strict liability for providers after the law's enactment. It explicitly allows exceptions for legitimate medical treatments and requires providers to prove such exceptions apply if challenged.

Maddy summaryThis bill requires Medicare Advantage plans to implement electronic pre-approval systems for medical services by 2028 and meet transparency reporting standards starting in 2027. Plans must publicly report data on approval/denial rates, appeal outcomes, response times, and technology use for pre-approval requests, including details on how denials relate to clinical criteria. It establishes a 24-hour response timeframe for certain requests and mandates annual reviews of pre-approval requirements based on data and input from seniors and providers. The law directly affects Medicare Advantage plans, seniors enrolled in these plans, and healthcare providers who submit pre-approval requests. These changes aim to make the pre-approval process faster, more transparent, and more accountable for seniors seeking covered medical services.